We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

A Study of Lung Clearance After Hypertonic Saline Delivery Using the tPAD Device

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02141191
Recruitment Status : Completed
First Posted : May 19, 2014
Last Update Posted : July 25, 2017
Parion Sciences
Information provided by (Responsible Party):
Tim Corcoran, University of Pittsburgh

Brief Summary:
The primary objective of this study is to determine whether a single overnight, eight-hour administration of a 7% NaCl solution delivered by the Parion Sciences transnasal Pulmonary Aerosol Delivery (tPAD) device has a significant effect on mucociliary clearance in subjects with cystic fibrosis, as compared to no treatment. This study will be conducted at the University of Pittsburgh Medical Center.

Condition or disease Intervention/treatment Phase
Cystic Fibrosis Drug: inhaled hypertonic saline (7%) Phase 1

Detailed Description:

Cystic Fibrosis (CF) lung disease is caused by dehydration of airway secretions that leads to mucus adhesion, infection and airways inflammation. A simple means to restore hydration to CF airway surfaces is to inhale hypertonic (3-7% NaCl) saline, which osmotically draws water onto the airway surface. Rehydration of the lubricant layer of the airway surface liquid facilitates mucociliary clearance (MCC) and therefore the removal of inhaled infectious agents. Recent studies have described (1) the short term (two weeks) beneficial effects of inhaled hypertonic saline (HS) four times daily on pulmonary function, MCC, and quality of life and (2) the long term (one year) benefits of inhaled HS twice daily on lung function and pulmonary exacerbation frequency. Consequently, inhaled HS is now used by ~55% of patients with CF nationwide. Due to the large number of medications that CF patients use on a daily basis in conjunction with airway clearance techniques, there is a high treatment burden that results in decreased quality of life.

Both the Cystic Fibrosis Foundation and leading CF clinicians support the idea that the use of hypertonic saline is now a standard of care. The investigators believe the use of a specialized transnasal Pulmonary Aerosol Delivery (tPAD) device for administration of HS will improve on that standard of care by reducing the treatment burden during CF patients' waking hours, ensuring greater compliance and potentially improving the efficacy and tolerability of inhaled HS.

A previous deposition study with the tPAD, in six healthy adult subjects, demonstrated ~38% of the 7% HS aerosol emitted from the nasal cannula is deposited in the adult lungs, with no acute safety or tolerability issues (Parion Sciences Protocol PS-D100-102; Scott Donaldson, PI). This deposition efficiency matched that of the Pari LC Star used via the oral route, which was used as a standard of practice comparator. However, 7% HS nebulization by the tPAD resulted in a more peripheral deposition of the aerosol than the Pari LC Star comparator.

Previously, it has been shown that administration of 5 mL of 7% HS QID by the Pari LC Star leads to a significant improvement in the lung function in CF patients. The investigators estimate that this dosing regimen deposits ~400 mg of NaCl per day but requires four ~18 minute administrations (deposition rate = 5.8 mg/min). Although HS is generally well tolerated in the CF population, intolerance does occur and is largely related to the rate of NaCl delivery to the oropharynx and airway surfaces. As nebulizer devices capable of administering aerosols through a nasal cannula are not currently available, Parion Sciences has designed a customized nebulizer spacer that entrains the aerosol from an approved and marketed Aerogen Aeroneb Pro vibrating mesh nebulizer into a nasal cannula without significant "rain out" or dripping from the cannula. The tPAD system being utilized has an output rate of ~50 ul/min, and so emits ~3.5 mg/min of NaCl and deposits ~1.3 mg/min in the lung (38% deposition efficiency). If used overnight for 8 hours, the investigators estimate that 640 mg NaCl will be deposited in the lung. Therefore, the investigators project that this novel administration system has the capacity to deliver approximately 50% greater mass of NaCl to the lung when used overnight, compared to 4 times a day treatment with a standard oral nebulizer, thereby potentially increasing efficacy. However, because the lung deposition rate is less than 25% that of the standard oral nebulizer, the investigators anticipate that the tPAD will also be better tolerated and will eliminate the need for daytime HS treatments. In this study, the investigators will explore the safety, tolerability and effect on mucociliary and absorptive clearance rates of a 7% HS solution administered continuously overnight via the transnasal route.

The tPAD is a non-significant risk device which is composed of a 510K approved Aerogen Aeroneb Pro vibrating mesh nebulizer with a custom nebulization chamber that allows for connection of a standard nasal cannula. Protocol PS-D201 is funded by NIH Grant 2R44HL110502-02 "Hypertonic Saline for Cystic Fibrosis".

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized Crossover Mucociliary Clearance Study of Aerosolized 7% NaCl Solution Administered Overnight by the tPAD Device to Subjects With Cystic Fibrosis
Study Start Date : June 2014
Actual Primary Completion Date : October 2015
Actual Study Completion Date : October 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cystic Fibrosis

Arm Intervention/treatment
Experimental: HS/sham
Subjects will utilize inhaled hypertonic saline (7%) delivered using the tPAD device during one session and perform a sham treatment with the tPAD during the other. The order will be randomized.
Drug: inhaled hypertonic saline (7%)
Inhaled hypertonic saline delivered by nasal cannula using the Parion transnasal Pulmonary Aerosol Delivery (tPAD) device
Other Name: PulmoSal 7% (pH+)

Experimental: sham/HS
Subjects will utilize inhaled hypertonic saline (7%) delivered using the tPAD device during one session and perform a sham treatment with the tPAD during the other. The order will be randomized.
Drug: inhaled hypertonic saline (7%)
Inhaled hypertonic saline delivered by nasal cannula using the Parion transnasal Pulmonary Aerosol Delivery (tPAD) device
Other Name: PulmoSal 7% (pH+)

Primary Outcome Measures :
  1. mucociliary clearance [ Time Frame: 6 hours ]
    Mucociliary clearance as assessed through the imaging of radiolabeled particles

Secondary Outcome Measures :
  1. safety and tolerability measurements [ Time Frame: 12 hours ]
    clinical adverse events assessment

  2. pulmonary function measurements [ Time Frame: 12 hours ]
    One-second forced expiratory volume (FEV1) and forced vital capacity (FVC) will be measured through breathing tests at the beginning and end of both testing visits.

  3. safety and tolerability measurements [ Time Frame: 12 hours ]
    Sleep tolerability questionnaire

  4. safety and tolerability measurements [ Time Frame: 12 hours ]
    Sino-nasal symptoms questionnaire

  5. safety and tolerability measurements [ Time Frame: 12 hours ]
    Assessment Of Device Experience

  6. DTPA absorption [ Time Frame: 6 hours ]
    Measurement of the absorptive clearance of Indium111-DTPA from the airways

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Has a diagnosis of CF via standard criteria
  • Is aged 18 years or older
  • Is capable of providing written informed consent in English to participate in the study.
  • Has a forced expiratory volume in 1 second (FEV1) >= 40% and < 110% predicted normal for age, gender, and height at Screening.
  • Has a body mass index (BMI) < 30 kg/m2
  • Can tolerate cessation of treatment with HS for 72 hours and rhDNase for 24 hours prior to each treatment visit until discharge from Visits 2 and 3.
  • Can tolerate cessation of treatment with long-acting beta-agonists (LABAs) for 12 hours and short-acting beta-agonists (SABAs) for 6 hours prior to radioaerosol administration for each MCC measurement and at least until discharge from Visits 2 and 3
  • Is on a stable medication regimen for at least 28 days before start of dosing and can continue such regimen for duration of study
  • Tolerates the 30 minute administration of 7% HS by the tPAD device at screening without subjective intolerance, oxyhemoglobin desaturation, or significant change in spirometry (>10% reduction from pre-dose value in FEV1, measured 30 minutes after completion of the aerosol administration)

Exclusion Criteria:

  • Has evidence of an acute upper or lower respiratory infection or clinically significant illness at screening or within 28 days prior to the start of dosing
  • Required an acute intervention with antibiotics (oral, inhaled, or IV) or systemic corticosteroids within the last 28 days for a respiratory illness
  • Has a history of intolerance to a beta-agonist or hypertonic saline
  • Has evidence of significant nasal obstruction that impairs the ability to breathe through the nose
  • Has a clinical diagnosis of sleep apnea
  • Has current symptoms of allergic rhinitis
  • Is unable to maintain a stable dosage regimen of any concomitant medication throughout the duration of the trial.
  • Has participated in a clinical drug or investigational device trial within the past 28 days
  • Has a history of positive test for Burkholderia cepacia
  • Has a present history of any clinically significant and uncontrolled neurologic, gastrointestinal, renal, hepatic, cardiovascular (including hyper/hypotension and tachy/bradycardia), psychological, pulmonary, metabolic, endocrine, or hematological disorder or disease, or any other major disorder or disease, in the opinion of the investigator
  • Has a history of smoking within the last 12 months
  • Is known to be pregnant, has a positive urine pregnancy test or is nursing (female subjects only)
  • Should not participate in the study, in the opinion of the Principal or Clinical investigator

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02141191

Layout table for location information
United States, Pennsylvania
University of Pittsburgh
Pittsburgh, Pennsylvania, United States, 15213
Sponsors and Collaborators
University of Pittsburgh
Parion Sciences
Layout table for investigator information
Principal Investigator: Joseph M Pilewski, MD University of Pittsburgh
Layout table for additonal information
Responsible Party: Tim Corcoran, Associate Professor of Medicine and Bioengineering, University of Pittsburgh
ClinicalTrials.gov Identifier: NCT02141191    
Other Study ID Numbers: PS-D201
First Posted: May 19, 2014    Key Record Dates
Last Update Posted: July 25, 2017
Last Verified: July 2017
Keywords provided by Tim Corcoran, University of Pittsburgh:
cystic fibrosis
hypertonic saline
nasal cannula
Additional relevant MeSH terms:
Layout table for MeSH terms
Cystic Fibrosis
Pathologic Processes
Pancreatic Diseases
Digestive System Diseases
Lung Diseases
Respiratory Tract Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases